ClinicalTrials.gg
RecruitingNCT07476729Updated Oct 26, 2026

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

A Phase 3 interventional study of Inotuzumab ozogamicin (INO) and Blinatumomab in B-Cell Acute Lymphoblastic Leukaemia, sponsored by Charite University, Berlin, Germany. Recruiting at 21 sites in 21 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Charite University, Berlin, Germany · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 26, 2026Now RecruitingFirst site in Norway+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies testing Inotuzumab Ozogamicin in Burkitt Lymphoma — 7 open to participants now, 12 under way, 3 of them phase 3. Inotuzumab Ozogamicin · Burkitt Lymphoma.

Planned enrollment
2nd of 18
750 · median 59
Started
2026
the only one that year
Phase 3
3 of 18
3 open now
Primary completion
2033-03
later than 11 of 11 live
Registered
17th of 18
by date
Lead sponsor
1 of 18
Charite University, Berlin, Germany

Among the 18 studies testing Inotuzumab Ozogamicin in Burkitt Lymphoma, this one is the 2nd largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 17th registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

7 of the 18 studies testing Inotuzumab Ozogamicin in Burkitt Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About Inotuzumab Ozogamicin

Inotuzumab Ozogamicin: first FDA approval 2017 (BESPONSA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Inotuzumab Ozogamicin in Burkitt Lymphoma, or all of them as a file.
02

Study summary

The IntReALL BCP 2020 study aims to review recent developments and findings regarding chemoimmunotherapy with inotuzumab and immunotherapy with blinatumomab and to increase the use of promising new immunotherapeutic drugs as replacements for toxic SOC chemotherapy elements.

The IntReALL BCP 2020 study has the potential to improve CR and EFS rates for all SR and HR groups, as well as for patients with IEM recurrence, by replacing toxic chemotherapy with targeted, less toxic immunotherapy strategies, and could establish these new approaches as SOC for children with relapsed BCP ALL in the future.

Read the detailed description

Though survival of children with acute lymphoblastic leukemia (ALL) has considerably improved over the past few decades, relapsed ALL remains a leading cause of mortality in children with cancer. Prognostic factors for patients with relapsed ALL are duration of first remission, immunophenotype of the malignant clone, site of relapse, molecular response to induction therapy (i.e minimal/measurable residual disease, MRD) and very high risk genetic features. The prognosis of patients with relapsed ALL was substantially improved with intensive multidrug chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the majority of patients at the cost of acute and long-term toxicity, including early and late treatment-related deaths. Patients with precursor B-cell (BCP) ALL classified as standard risk (SR) with late isolated bone marrow (BM) or combined with extramedullary (EM) disease and without high risk genetic features achieve high remission rates (> 95%) and favorable event-free survival (EFS) rates (65%) with conventional consolidation and maintenance chemotherapy if, after induction therapy, the leukemia could be reduced below the MRD level of 10-3 or 10-4, depending on the induction regimen. About 50% of SR patients experience poor MRD response after conventional chemotherapy induction and require intensified consolidation through allo-HSCT with total body irradiation to achieve EFS rates comparable to that of SR patients with good MRD response. Patients classified as high risk (HR) with early BM/EM relapse still demonstrate poor CR rates of around 65-75% being treated on standard induction therapy, and high rates of subsequent relapse. Consequently, these patients all require allo-HSCT for consolidation of 2nd remission. Patients with isolated extramedullary relapse (IEM) had a better outcome with CNS directed induction / consolidation chemotherapy as provided with the ALL-REZ BFM backbone compared to conventional induction as provided with the ALL-R3 induction. Patients with very high risk (VHR) genetic features (KMT2A::AFF1, TCF3::PBX1, TCF3::HLF rearrangements, low hypodiploidy/near haploidy, TP53 alterations) and/or very early relapses (i.e. those occurring within 18 month after initial diagnosis) have a limited benefit from conventional chemotherapy followed by allo-HSCT since their EFS rates have been reported to be below 20%.

For SR and HR patients, there is a need to replace toxic induction/consolidation chemotherapy with targeted less toxic drugs and to improve the rates of MRD negative remission after induction. In SR patients, reduction of MRD after induction could result in a lower proportion of patients with indication for allo-HSCT, a treatment that - despite being efficacious - is associated with substantial long-term sequelae. For SR patients, there is a medical need to reduce toxic consolidation and maintenance chemotherapy with targeted less toxic and potentially more effective treatment. The CD3/19 directed bi-specific monoclonal antibody blinatumomab has shown better efficacy and less toxicity compared to conventional consolidation chemotherapy in children with relapsed B-cell precursor (BCP) ALL with and without extramedullary involvement in randomized trials. The superiority of blinatumomab has been shown for HR patients before receiving HSCT in a randomized trial in Europe and for HR/IR patients before receiving HSCT and SR patients with MRD good response in a randomized trial conducted by the Children's Oncology Group. In SR patients with MRD good response, a total of 3 courses of Blinatumomab has been applied partly replacing consolidation chemotherapy and partly as add on to the standard therapy. Thus, blinatumomab can be considered as best standard of care (SOC) for early consolidation in this indication. Blinatumomab is currently being developed for subcutaneous administration. This formulation is planned to be tested in phase I/II studies in children with BCP ALL at the end of 2025. Innovative, more efficacious therapies, such as CD19-targeting CAR T cells, are urgently needed for VHR patients, since conventional therapies, including allo-HSCT, have led to dismal results.

Inotuzumab ozogamicin (InO) is a CD22 directed humanized monoclonal antibody linked to the toxin calicheamicin, belonging to the class of antibody-drug conjugate (ADC). CD22 is expressed on nearly all BCP-ALLs. After antigen binding, InO is internalized and the toxin released causing DNA damage and inducing apoptosis. InO has shown high MRD negative remission rates compared to SOC in adult and pediatric patients with relapsed/refractory BCP ALL and a safe and effective dose has been identified in a pediatric phase I/II trial.

The trial IntReALL BCP 2020 aims at integrating these recent developments and findings and at increasing the use of promising new immune-therapeutic drugs replacing toxic SOC chemotherapy elements. SR patients with bone marrow relapse will randomly receive the SOC induction ALLR3 with Mitoxantrone or InO monotherapy. Post induction, they will receive a 1st consolidation chemotherapy element (SCB1). Patients with MRD good response (\< 10-4) will receive 3 courses of blinatumomab during consolidation and maintenance therapy, the 1st replacing the consolidation chemotherapy element SCB2, the 2nd added on after the 3rd consolidation chemotherapy element SCB3, and the 3rd added on after the 4rth consolidation element SCB4 and 8 weeks of conventional maintenance therapy, which, at difference of the IntReALL 2010 trial will not include vincristine/dexamethasone pulses. SR patients with MRD poor response will receive SCB1 and one blinatumomab course followed by allo-HSCT. During the course of the trial, the protocol is planned to be amended changing the blinatumomab formulation from IV to SC as soon as the latter becomes available. .

HR patients with bone marrow relapse will be included into an industry sponsored induction window trial and will join the academic IntReALL BCP 2020 study only for consolidation, since all HR patients have an indication for allo-HSCT. HR patients in CR2 after induction will receive one course of consolidation chemotherapy (HC1), one course of blinatumomab as recently established SOC followed by allo-HSCT. Whereas for the European Blina-215 trial (randomized blinatumomab versus HC3) 2 courses HC1 and HC2 were given as standard early consolidation, in the COG trial (AALL1331) the whole consolidation chemotherapy has been replaced by blinatumomab. One standard chemotherapy consolidation course HC1 is considered as feasible compromise and provides time for B-cell regeneration after InO as prerequisite for T-cell expansion during the blinatumomab consolidation course.

Patients with IEM will receive the IntReALL SR2010 arm A backbone with blinatumomab replacing the chemotherapy element SCA3 as bridge to allo-HSCT in those with early relapse or to further consolidation therapy in those with late relapse.

The hypotheses addressed within the IntReALL BCP 2020 trial are, that:

  1. EFS-probability in SR patients will be improved in the InO arm leading to higher CR rates, better MRD response and to less patients requiring allo-HSCT compared to standard of care induction chemotherapy ALL R3 in a prospective randomized trial.
  2. SR patients with MRD good response will have a better DFS probability with 3 courses of blinatumomab, the 1st replacing the consolidation chemotherapy element SCB2, the 2nd added on after the consolidation chemotherapy element SCB3, and the 3rd added on after the consolidation element SCB4 and 8 weeks of conventional maintenance therapy, followed by maintenance therapy until week 132, being applied without vincristine/dexamethasone pulses, as compared to historical controls. Blinatumomab given subcutaneously is planned to be investigated accordingly after finalization of the recruitment for the IV trial within a planned amendment of the study.
  3. HR patients with CR2 after induction will have a non-inferior DFS with HC1 and blinatumomab compared to historical controls with HC1, HC2 and blinatumomab.
  4. EFS probability in patients with IEM relapse will be improved and toxicity will be reduced with blinatumomab as late consolidation element compared to historical controls (ALL-REZ BFM 2002).

The IntReALL BCP 2020 trial has the potential to improve CR and EFS rates for all SR and HR groups, as well as in patients with IEM relapse, by replacing toxic chemotherapy with targeted less toxic immunotherapy strategies and may establish these new approaches as SOC for children with relapsed BCP ALL in future. In addition, the IntReALL BCP 2020 trial has the ambition to reduce the proportion of SR patients in need of an allograft for consolidation therapy.

03

Conditions studied

  • B-Cell Acute Lymphoblastic Leukaemia

Browse trials for

Keywords

  • Lymphoblastic
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For all study questions:

  • Confirmed diagnosis of 1st B-cell precursor ALL
  • Patients ≥ 1 year and less than 18 years of age at diagnosis of primary ALL and less than 21 years of age at date of inclusion into the study
  • Patient enrolled in a participating center
  • Written (IC)
  • Start of treatment falling into the study period
  • No participation in other clinical trials 30 days prior to study enrolment that interfere with this protocol, except trials for primary ALL

Specific for SR induction randomization:

  • Meeting SR criteria
  • BM involvement (≥ 5% or ≥ 1% leukemic blasts confirmed by 2 quantitative methods)
  • CD22 positive ALL (>80% confirmed by flow-cytometry)
  • No previous history of veno-occlusive disease (VOD)/ sinusoidal obstruction syndrome (SOS)

Specific for SR MRD poor response consolidation:

  • Meeting SR criteria with bone marrow involvement at relapse diagnosis
  • M1/CR2 and MRD ≥ 10-4 after induction
  • CD19 positive ALL at relapse (>10%)

Specific for SR MRD good response consolidation:

  • Meeting SR criteria with bone marrow involvement at relapse diagnosis
  • M1/CR2 and MRD \< 10-4 after induction
  • CD19 positive ALL at relapse (>10%) Specific for HR consolidation arm
  • Meeting HR or VHR (in case of no possibility to be treated with CAR T cells) criteria
  • M1/CR2 after induction therapy
  • CD19 positive ALL at relapse (>10%)

Specific for IEM arm:

  • Histology or cytology proven extramedullary relapse
  • No bone marrow involvement (M1 at relapse diagnosis) and bone marrow MRD \<1%
  • CD19 positive ALL at relapse (>10%)

Exclusion criteria

Exclusion Criteria:

  • Known to the active substances or of the IMP's or the SOC drugs, except to PEG-asparaginase which can be replaced by Erwinase
  • (LVEF) \< 50% or fractional shortening \< 25%, and/or current or prior treatment for cardiomyopathy and/or history of arrhythmias
  • Pregnancy or positive pregnancy test in female patients (urine sample positive for β-HCG > 10 U/l) at screening or within 7 days prior to the initiation of study treatment
  • Sexually active adolescents and adults not willing to use highly effective method (pearl index \<1) until 12 months after end of anti-leukemic therapy
  • Women not willing to refrain from breast feeding until 12 months after end of anti-leukemic therapy
  • Relapse post HSCT
  • Relapse post chimeric antigen receptor T-cell (CAR-T) therapy
  • The whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian
  • Objection to the study participation by a minor patient
  • Patients in a dependent or subordinate relationship to the investigator or site staff (e.g. employees, relatives, or students)
  • No consent is given for saving and propagation of pseudonymized medical data for study reasons
  • Patients with any concurrent medical condition, laboratory abnormality, concomitant treatment, or comorbidity that, in the investigator's clinical judgment would

    • compromise the patient's ability to safely receive or tolerate inotuzumab ozogamicin and/or blinatumomab
    • significantly interfere with assessment of treatment efficacy or safety
    • make it unlikely that the patient would derive clinical benefit from protocol therapy
    • preclude adherence to study procedures or follow-up requirements
  • Subjects unwilling or unable to comply with the study procedures
  • Subjects who are legally detained in an official institute

Specific for SR induction randomization:

  • Prior confirmed severe (grade 3 or 4) or ongoing VOD/SOS
  • Serious ongoing hepatic disease (e.g., cirrhosis, active hepatitis) not related to the current ALL relapse or current diagnostic/therapeutic measures
  • > 2,5 x (at relapse diagnosis before start of cytoreduction) and/or > 1.5 x ULN
  • Patients with intolerance to PEG-asparagniase and also to Erwinase are stratified to the inotuzumab arm
  • Patients with insufficient expression of CD22 (\< 80%) on leukemic blasts, they are assigned to the control chemotherapy arrm

Specific for blinatumomab treatment:

  • Clinically relevant CNS pathology requiring treatment (eg, unstable epilepsy)
  • Evidence of current CNS (CNS 2, CNS 3) involvement by ALL. Subjects with CNS relapse at the time of relapse are eligible if CNS is successfully treated prior to enrollment

Allowed systemic diseases and concomitant medication

  • Patients with Down Syndrome (DS) can be included as separate and descriptive population, not joining the study questions. Those with BM involvement receive inotuzumab ozogamicin for induction without randomization. HR patients and SR patients with MRD poor response will be allocated to allo-HSCT indication, or in case CD19 directed CAR-T-cell therapy off-protocol as individualized treatment approach. Patients with MRD good response will get the SR consolidation and maintenance therapy. Those with IEM profile will be treated according to the IEM stratum. Patients not expressing sufficiently CD22 and/or CD19 will receive the respective chemotherapy strategy.
  • Patients with BCR::ABL positive (Ph+) or BCR::ABL like (Ph-like) BCP ALL with TKI treatment option can be included as separate and descriptive population, not joining the study questions. Those with BM involvement receive inotuzumab ozogamicin plus TKI (investigators choice) without randomization for induction followed by HC1 and blinatumomab plus TKI followed by allo-HSCT. Those with IEM profile will be treated according to the IEM stratum plus TKI. Patients not expressing sufficiently CD22 and/or CD19 will receive the respective chemotherapy strategy.
  • Patients with systemic diseases such as cystic fibrosis or diabetes may be eligible for enrolment in this study only if they presumably will tolerate the protocol treatment and primary dose reductions would not be necessary.
  • Any kind of concomitant medication given due to medical reasons is allowed. Incompatibilities and drug interactions with the study medications are listed in the appendix. In case of expected adverse interactions, concomitant therapies should be changed to alternative less problematic agents if possible

Prohibited medication

  • Antileukemic therapy other than scheduled in the protocol (except cytoreductive pre-phase with dexamethasone)
  • drugs other than scheduled in the protocol
  • Attenuated which are strictly prohibited during and until 6 months after end of chemotherapy or 18 months after allo-HSCT
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
750 participants (estimated)

Study arms

  • Active comparator
    SR induction

    prospective, randomized 1:1, open label phase II/III trial comparing arm AI (ALLR3-MITOX) versus arm BI (InO). Randomization is stratified according to frontline treatment group (BFM, AIEOP, ALLTogether, other) and localization of relapse (BM+CNS, other)

    Drug: Inotuzumab ozogamicin (INO)

  • Active comparator
    SR MRD good response, consolidation

    single arm trial with 3 courses of blinatumomab, the 1st replacing the consolidation chemotherapy element SCB2, the 2nd added on after the consolidation chemotherapy element SCB3, and the 3rd added on after the consolidation element SCB4 and 8 weeks of conventional maintenance therapy, then followed by conventional maintenance therapy being applied without reinduction chemotherapy pulses until week 132, as compared to historical controls (IntReALL BCP 2020 SR SOC induction arm compared with IntReALL SR 2010 arm B without epratuzumab)

    Drug: Blinatumomab

  • Active comparator
    HR with CR2, consolidation

    single arm trial with HC1 and 1 course of blinatumomab followed by allo-HSCT compared with historical controls

    Drug: Blinatumomab

  • Active comparator
    Isolated extramedullary manifestations

    single arm trial with the IntReALL SR 2010 Arm A (ALL-REZ BFM 2002) including blinatumomab replacing the chemotherapy element SCA3 compared with historical controls. SR patients will receive further conventional consolidation, local irradiation and maintenance, HR patients will be given allo-HSCT after blinatumomab

    Drug: Blinatumomab

Interventions

06

What researchers measure

Primary outcomes

  1. SR induction EFS

    timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up

    Time frame: From enrollment until 2 years after end of treatment

  2. SR-MRD good response consolidation DFS

    timespan of survival after achievnemt of eremission until endpoint relevant event (death in remission, relapse, secondary malignancy) or until end of follow up

    Time frame: From enrollment until 2 years after end of treatment

  3. HR with CR2 consolidation DSF

    timespan of survival after achievnemt of eremission until endpoint relevant event (death in remission, relapse, secondary malignancy) or until end of follow up

    Time frame: From enrollment until 2 years after end of treatment

  4. Isolated extramedullary manifestations: EFS

    timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up

    Time frame: From enrollment until 2 years after end of treatment

  5. SR induction: Pharmacokinetics Inotuzumab

    cumulative area under the concentration-time curve (AUC)

    Time frame: from enrollment until day 28

Secondary outcomes

  1. SR induction: MRD

    MRD negativity rate after induction quantified by flow- and/or PCR techniques

    Time frame: Day 28 of induction

  2. SR-MRD good response consolidation: OS

    timespan of survival until death or until end of follow up

    Time frame: From enrollment until 2 years after end of treatment

  3. Isolated extramedullary manifestations: EFS

    timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up

    Time frame: From enrollment until 2 years after end of treatment

  4. SR induction: allo-HSCT

    Proportion of patients requiring allo-HSCT

    Time frame: week 14 to 20 after enrollment

  5. SR induction: OS

    timespan of survival until death or until end of follow up

    Time frame: from enrollment until 2 years after end of treatment

  6. SR induction: Toxicity

    Toxicity (assessed by CTCAE grades and SAE reports)

    Time frame: from enrollement until end of protocol therapy

  7. SR induction: CD19 positive cells

    Rate of patients with CD19 positive cells after SCB1 prior to Blinatumomab

    Time frame: week 9 after enrollment

  8. SR-MRD good response consolidation: Toxicity

    Toxicity (quantified by CTCAE grades and SAE reports)

    Time frame: from enrollment until end of treatment (week 132)

  9. Isolated extramedullary manifestations: OS

    timespan of survival until death or until end of follow up

    Time frame: from enrollment until 2 years after end of treatment

  10. Isolated extramedullary manifestations: DFS by MRD

    timespan of survival after achievnemt of eremission until endpoint relevant event (death in remission, relapse, secondary malignancy) or until end of follow up by MD after induction (cut-off 10-4)

    Time frame: from enrollment until 2 years after end of treatment

  11. HR with CR2 consolidation: OS

    timespan of survival until death or until end of follow up

    Time frame: from enrollment until 2 years after end of treatment

  12. HR with CR2 consolidation: Toxicity

    Toxicity (assessed by CTCAE grades and SAE reports)

    Time frame: from enrollment until end of treatment (day 100 post HSCT)

  13. HR with CR2 consolidation: MRD

    MRD negativity rates before allo-HSCT quantified by flow- and/or PCR techniques

    Time frame: week 13 after enrollment

  14. HR with CR2 consolidation: allo-HSCT

    allo-HSCT rates

    Time frame: week 14 after enrollment

  15. Inotuzumab PK

    Maximum and through concentrations of inotuzumab

    Time frame: from enrollment until end of induction (day 28), before and 1 hour after start of inotuzumab infusion

  16. Inotuzumab PK exposure response relationship

    CR- and MRD negativity rates by inotuzumab AUC

    Time frame: from enrollment until end of induction (day 28)

07

Study locations

9 of 21 sites recruiting
08

References and documents

Publications

  • Eckert C, Parker C, Moorman AV, Irving JA, Kirschner-Schwabe R, Groeneveld-Krentz S, Revesz T, Hoogerbrugge P, Hancock J, Sutton R, Henze G, Chen-Santel C, Attarbaschi A, Bourquin JP, Sramkova L, Zimmermann M, Krishnan S, von Stackelberg A, Saha V. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021 Jul;151:175-189. doi: 10.1016/j.ejca.2021.03.034. Epub 2021 May 16. PubMed 34010787 ↗
  • Hagedorn N, Acquaviva C, Fronkova E, von Stackelberg A, Barth A, zur Stadt U, Schrauder A, Trka J, Gaspar N, Seeger K, Henze G, Cave H, Eckert C; Resistant Disease Committee of the International BFM study group. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood. 2007 Dec 1;110(12):4022-9. doi: 10.1182/blood-2007-04-082040. Epub 2007 Aug 24. PubMed 17720883 ↗
  • Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grumayer R, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Schrauder A, Escherich G, Sramkova L, Niggli F, Hitzler J, von Stackelberg A. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013 Jul 20;31(21):2736-42. doi: 10.1200/JCO.2012.48.5680. Epub 2013 Jun 17. PubMed 23775972 ↗
  • Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, Poetschger U, Stachel D, Schrappe M, Alten J, Schrauder A, Schulz A, Lang P, Muller I, Albert MH, Willasch AM, Klingebiel TE, Peters C. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015 Apr 10;33(11):1275-84. doi: 10.1200/JCO.2014.58.4631. Epub 2015 Jan 20. PubMed 25605857 ↗
  • Lissat A, van Schewick C, Steffen IG, Arakawa A, Bourquin JP, Burkhardt B, Henze G, Mann G, Peters C, Sramkova L, Eckert C, von Stackelberg A, Chen-Santel C. Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma-A Report from the ALL-REZ Study Group. J Clin Med. 2021 Nov 14;10(22):5292. doi: 10.3390/jcm10225292. PubMed 34830574 ↗
  • Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M, Cario G, Cazzaniga G, Escherich G, Harrison CJ, Heyman M, Hunger SP, Kiss C, Liu HC, Locatelli F, Loh ML, Manabe A, Mann G, Pieters R, Pui CH, Rives S, Schmiegelow K, Silverman LB, Stary J, Vora A, Brown P. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood. 2022 Mar 24;139(12):1785-1793. doi: 10.1182/blood.2021012328. PubMed 34192312 ↗
  • von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016 Dec 20;34(36):4381-4389. doi: 10.1200/JCO.2016.67.3301. Epub 2016 Oct 31. PubMed 27998223 ↗
  • Brivio E, Locatelli F, Lopez-Yurda M, Malone A, Diaz-de-Heredia C, Bielorai B, Rossig C, van der Velden VHJ, Ammerlaan ACJ, Thano A, van der Sluis IM, den Boer ML, Chen Y, Sleight B, Brethon B, Nysom K, Sramkova L, Ora I, Vinti L, Chen-Santel C, Zwaan CM. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021 Mar 25;137(12):1582-1590. doi: 10.1182/blood.2020007848. PubMed 33067614 ↗
  • Wu JH, Pennesi E, Bautista F, Garrett M, Fukuhara K, Brivio E, Ammerlaan ACJ, Locatelli F, van der Sluis IM, Rossig C, Chen-Santel C, Bielorai B, Petit A, Stary J, Diaz-de-Heredia C, Rives S, O'Marcaigh A, Rizzari C, Engstler G, Nysom K, Rubio-San-Simon A, Bruno B, Bertrand Y, Brethon B, Rialland F, Plat G, Dirksen U, Sramkova L, Zwaan CM, Huitema ADR. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059. Clin Pharmacokinet. 2024 Jul;63(7):981-997. doi: 10.1007/s40262-024-01386-z. Epub 2024 Jun 22. PubMed 38907948 ↗
  • Stock W, Martinelli G, Stelljes M, DeAngelo DJ, Gokbuget N, Advani AS, O'Brien S, Liedtke M, Merchant AA, Cassaday RD, Wang T, Zhang H, Vandendries E, Jabbour E, Marks DI, Kantarjian HM. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 Mar 15;127(6):905-913. doi: 10.1002/cncr.33321. Epub 2020 Nov 24. PubMed 33231879 ↗
  • Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Burger B, Rives S, Bielorai B, Rossig C, Petit A, Rizzari C, Engstler G, Stary J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F, Zwaan CM. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia. 2022 Jun;36(6):1516-1524. doi: 10.1038/s41375-022-01576-3. Epub 2022 Apr 25. PubMed 35468945 ↗
  • Rabik CA, Wang S, Chadda R, Przepiorka D, Vallejo J, Jiang X, Theoret MR, de Claro RA. FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy. Clin Cancer Res. 2025 Oct 15;31(20):4230-4238. doi: 10.1158/1078-0432.CCR-25-1034. PubMed 40828516 ↗
  • Mejstrikova E, Klinger M, Markovic A, Zugmaier G, Locatelli F. CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab. Pediatr Blood Cancer. 2021 Dec;68(12):e29323. doi: 10.1002/pbc.29323. Epub 2021 Sep 14. PubMed 34519430 ↗
  • Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Mergen N, Mohammad A, Kormany WN, Eckert C, Moricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, von Stackelberg A. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021 Mar 2;325(9):843-854. doi: 10.1001/jama.2021.0987. PubMed 33651091 ↗
  • Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023 May 2;16(1):44. doi: 10.1186/s13045-023-01444-2. PubMed 37131217 ↗
  • Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16. PubMed 36402146 ↗
  • Foa R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, Ferrara F, Lunghi M, Mule A, Bonifacio M, Fracchiolla N, Salutari P, Fazi P, Guarini A, Rambaldi A, Chiaretti S. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL. J Clin Oncol. 2024 Mar 10;42(8):881-885. doi: 10.1200/JCO.23.01075. Epub 2023 Dec 21. PubMed 38127722 ↗
  • Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, Raetz EA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Pulsipher MA, Hunger SP, Loh ML. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021 Mar 2;325(9):833-842. doi: 10.1001/jama.2021.0669. PubMed 33651090 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2033, 78 months after the start.

Of 19 phase 3 interventional studies under Burkitt Lymphoma, half reached primary completion within 106 months of starting (the median), counting those still running; a quarter within 78 and three quarters within 119. This study's planned 78 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Sep 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 17, 2026
StartActual
Sep 1, 2026was Apr 2026
Primary completionEst.
Mar 31, 2033
CompletionEst.
Mar 31, 2033
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
1 site added — first site in Norway. 20 sites changed recruiting status (12 now not yet recruiting, 8 now recruiting)
Show 20 sites
  • St. Anna Kinderspital GmbH · Vienna, Austriano status→Recruiting
  • Ghent University Hospital · Ghent, Belgiumno status→Not yet recruiting
  • Fakultni Nemocnice V Motole · Prague, Czechiano status→Recruiting
  • Rigshospitalet · Copenhagen, Denmarkno status→Recruiting
  • HUS Helsinki University Hospital · Helsinki, Finlandno status→Not yet recruiting
  • CHU de NICE, Hôpital L'ARCHET · Nice, Franceno status→Recruiting
  • Charité - Universitätsmedizin Berlin · Berlin, Germanyno status→Recruiting
  • Semmelweis University · Budapest, Hungaryno status→Not yet recruiting
  • Tel Aviv Sourasky Medical Centre Dana-Dwek Children's Hospital · Tel Aviv, Israelno status→Not yet recruiting
  • Ospedale Pediatrico Bambino Gesu · Rome, Italyno status→Not yet recruiting
  • Prinses Máxima Centrum · Utrecht, Netherlandsno status→Recruiting
  • University Wroclaw · Wroclaw, Polandno status→Not yet recruiting
  • Instituto Português de Oncologia de Lisboa · Lisbon, Portugalno status→Not yet recruiting
  • Fundeni Clinical Institute, Pediatric Clinic Fundeni · Bucharest, Romaniano status→Not yet recruiting
  • Univerzity Komenského a Národného · Bratislava, Slovakiano status→Not yet recruiting
  • University Medical Centre Ljubljana · Ljubljana, Sloveniano status→Not yet recruiting
  • University Clinical Hospital Virgen De La Arrixaca · Murcia, Spainno status→Recruiting
  • Karolinska University Hospital · Solna, Swedenno status→Recruiting
  • University Children's Hospital · Zurich, Switzerlandno status→Not yet recruiting
  • Acıbadem University · Istanbul, Turkey (Türkiye)no status→Not yet recruiting
Show site
  • Oslo University Hospital · Oslo, Norway
Oct 26, 2026
Start date
Apr 1, 2026→Sep 1, 2026 (actual)
Oct 26, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Charité - Universitätsmedizin Berlin · Berlin, GermanyContact a•••@charite.de · •••6833→a•••@charite.de · •••6833
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Norway. 20 sites changed recruiting status (12 now not yet recruiting, 8 now recruiting)
    Show 20 sites
    • St. Anna Kinderspital GmbH · Vienna, Austriano status→Recruiting
    • Ghent University Hospital · Ghent, Belgiumno status→Not yet recruiting
    • Fakultni Nemocnice V Motole · Prague, Czechiano status→Recruiting
    • Rigshospitalet · Copenhagen, Denmarkno status→Recruiting
    • HUS Helsinki University Hospital · Helsinki, Finlandno status→Not yet recruiting
    • CHU de NICE, Hôpital L'ARCHET · Nice, Franceno status→Recruiting
    • Charité - Universitätsmedizin Berlin · Berlin, Germanyno status→Recruiting
    • Semmelweis University · Budapest, Hungaryno status→Not yet recruiting
    • Tel Aviv Sourasky Medical Centre Dana-Dwek Children's Hospital · Tel Aviv, Israelno status→Not yet recruiting
    • Ospedale Pediatrico Bambino Gesu · Rome, Italyno status→Not yet recruiting
    • Prinses Máxima Centrum · Utrecht, Netherlandsno status→Recruiting
    • University Wroclaw · Wroclaw, Polandno status→Not yet recruiting
    • Instituto Português de Oncologia de Lisboa · Lisbon, Portugalno status→Not yet recruiting
    • Fundeni Clinical Institute, Pediatric Clinic Fundeni · Bucharest, Romaniano status→Not yet recruiting
    • Univerzity Komenského a Národného · Bratislava, Slovakiano status→Not yet recruiting
    • University Medical Centre Ljubljana · Ljubljana, Sloveniano status→Not yet recruiting
    • University Clinical Hospital Virgen De La Arrixaca · Murcia, Spainno status→Recruiting
    • Karolinska University Hospital · Solna, Swedenno status→Recruiting
    • University Children's Hospital · Zurich, Switzerlandno status→Not yet recruiting
    • Acıbadem University · Istanbul, Turkey (Türkiye)no status→Not yet recruiting
    Show site
    • Oslo University Hospital · Oslo, Norway
    Start date Apr 1, 2026→Sep 1, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Charité - Universitätsmedizin Berlin · Berlin, GermanyContact a•••@charite.de · •••6833→a•••@charite.de · •••6833
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07476729
Responsible party
PD Dr. Arend von Stackelberg (Prof. Dr. med, Charite University, Berlin, Germany) — Principal investigator
First posted
Mar 17, 2026
Start date
Sep 1, 2026
Primary completion
Mar 31, 2033 (estimated)
Completion
Mar 31, 2033 (estimated)
Last update
Oct 26, 2026

Study contacts

Adriane E Napp, Dr. rer. medic, MSc
Contact
adriane.napp@charite.de
+17654426233
Arend von Stackelberg, Dr. med., MD
principal investigator · Charité - Universitätsmedizin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Inotuzumab Ozogamicin · Blinatumomab

Start the discussion